A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4830-4840

  Alsina, Melissa ^a   Trudel, Suzanne ^b   Furman, Richard R ^c   Rosen, Peter J ^e   O'Connor, Owen A ^d   Comenzo, Raymond L ^f   Wong, Alvin ^g   Kunkel, Lori A ^h   Molineaux, Christopher J ⁱ   Goy, Andre ^j  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Tower Cancer Research Foundation ^*  (United States)

^f TUFTS UNIVERSITY   (United States)

^g ONYX PHARMACEUTICALS   (United States)

^h Independent Consultant   (United States)

ⁱ CJM Consulting   (United States)

^j John Theurer Cancer Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; DEXAMETHASONE; PROTEASOME;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOXIA; INSOMNIA; LARGE CELL LYMPHOMA; LARYNX PAIN; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PANCREATITIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SHOULDER PAIN; SIDE EFFECT; SORE THROAT; T CELL LYMPHOMA; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; RECURRENCE;

EID: 84865712581     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3007     Document Type: Article

References (27)

1. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009;23:19647-79.
2. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
3. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-79.
4. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-95.
5. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997;386:463-71.
6. Bennett MK, Kirk CJ. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 2008;11: 616-25.
7. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64.
8. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955-60.
9. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91.
10. Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors. J Amer Chem Soc 2000;122:1237-8.
11. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
12. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17:2734-43.
13. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90.
14. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91.
15. Jagannath S, Vij R, Stewart K, Somlo G, Jakubowiak A, Trudel S, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 27:15s, 2009 (suppl; abstr 8504).
16. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
18. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Blade J, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:127-31.
19. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: U. S. National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program. 2006.
20. Kirk CJ, Jiang J, Muchamuel T, Dajee M, Swinarski D, Aujay M, et al. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration. Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 2765.
21. Palumbo A, Mateos MV, Bringhen S, San Miguel JF. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 2011;25:181-91.
22. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84.
23. Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011;67:57-67.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
25. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489-99.
26. Stewart AK, Kaufman JL, Jakubowiak AJ, Jagannath S, Kukreti V, McDonagh KT, et al. The effect of carfilzomib (CFZ) in patients (pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): updated results from the PX-171-004 study. J Clin Oncol 29: 2011 (suppl; abstr 8026).
27. Siegel D, Wang L, Orlowski RZ, Kaufman JL, Stewart AK, Kukreti V, et al. PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood (ASH Annual Meeting Abstracts) 2009;114:Abstract 303.